NVIDIA Crushes Earnings--But One $8 Billion Problem Could Haunt Its AI Future
Warning! GuruFocus has detected 4 Warning Signs with NVDA.
But there's a twist in the story: new U.S. export restrictions on NVIDIA's H20 AI chips to China slammed the brakes on a key revenue stream. The company recorded a $4.5 billion charge for unsold H20 inventory and missed out on another $2.5 billion in potential sales last quarter. It's bracing for an $8 billion hit this coming quarter. That said, NVIDIA still sees Q2 revenue coming in around $45 billion, and is guiding gross margins to reach into the low-70% range, even with China off the table.
Huang struck a confidentbut measuredtone, signaling that AI infrastructure is fast becoming as vital as electricity. NVIDIA's global expansion efforts and continued partnershipswith the likes of Google, Oracle, and Foxconncould cushion some of the blow from China. Still, with geopolitical risk rising and regulation tightening, this next leg of the AI cycle may get bumpy. Investors may want to watch how fast those international AI factories scaleand whether demand holds as NVIDIA navigates this new global chessboard.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
MicroStrategy earnings beats expectations by over 35,000%
MicroStrategy earnings beats expectations by over 35,000% originally appeared on TheStreet. MicroStrategy (NASDAQ: MSTR) posted outstanding quarterly earnings of $32.52 per share, above the average expectation of -$0.09 by 35,447.83%. This is a 4,378.95% improvement over the -$0.76 per share loss posted in the same period previous year. The firm also reported sales of $114.49 million, which was slightly more than the projected $112.96 million and above projections by 1.35%. Sales increased 2.73% from $111.44 million in the same quarter a year earlier. Strategy, previously known as MicroStrategy, is the world's first and largest Bitcoin Treasury Company. These results come on the heels of Strategy increasing its preferred 'Stretch' stock offering to fund $2.47 billion to cover additional Bitcoin purchases. Previous quarter EPS losses Strategy's financial performance has been far from steady over the past ten years; its recent trajectory was primarily due to its aggressive buying of Bitcoin. MicroStrategy's profits have been somewhat volatile, primarily and likely due to the company's significant investment in corporation reported a substantial loss in the first quarter of 2025, amounting to -$16.49 per share, which was far worse than the expected -$2.44. This was a 575% negative earnings surprise. This happened following a string of growing losses in 2024. Earnings Per Share (EPS) for the fourth quarter was -$3.03, representing a 3,214% surprise compared to the prediction of -$0.09. EPS for the third quarter was -$1.72, a 1,298% surprise compared to the predicted -$0.12. This trend follows a longer-term pattern: MicroStrategy made steady but small profits from 2010 to 2019, but its recent turn to Bitcoin has amplified its earnings fluctuations. The habit of underperformance began in the first quarter of 2024, when EPS missed its expectation of -$0.05 by -$0.31. The second quarter of 2023, on the other hand, had a +900% surprise, with EPS of $0.15 instead of the expected -$0.02. These significant changes indicate that MicroStrategy's finances remain highly sensitive to fluctuations in the crypto market, as pointed by analysts, making it challenging for traditional investors to estimate earnings and understand the company's financials. The company is also going to discuss its second quarter results in a webinar at 5PM ET. MicroStrategy earnings beats expectations by over 35,000% first appeared on TheStreet on Jul 31, 2025 This story was originally reported by TheStreet on Jul 31, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
Materials Dividends Spotlight: Linde's (LIN) Consistent Payout and Global Reach
Linde plc (NASDAQ:LIN) is included among the 13 Best Materials Dividend Stocks to Buy Right Now. A scientist in a lab coat inspecting a cylinder filled with industrial gas. Linde plc (NASDAQ:LIN) holds the position as the leading industrial gas company globally, providing a wide variety of gases used across multiple industries. Its main operations center around atmospheric gases like oxygen and nitrogen, along with process gases such as carbon dioxide and hydrogen. The stock has surged by over 3% since the start of 2025. In recent years, Linde plc (NASDAQ:LIN) has placed greater emphasis on clean energy initiatives and securing long-term contracts with clients. It has also advanced its technological capabilities, particularly in hydrogen technologies and specialized gas processing methods. The company's broad global presence and exclusive technologies have played a significant role in driving its continued growth. On July 29, Linde plc (NASDAQ:LIN) declared a quarterly dividend of $1.50 per share, which was in line with its previous dividend. The company has overall raised its payouts for 32 consecutive years. As of July 29, the stock supports a dividend yield of 1.29%. While we acknowledge the potential of LIN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Business Upturn
an hour ago
- Business Upturn
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) ('Silexion Therapeutics' or the 'Company'), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company's ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 304,212 of the Company's ordinary shares. The new warrants will have an exercise price of $11.32 per share, will be exercisable upon the effective date of the increase of the Company's authorized ordinary shares following shareholder approval and will have a term of twenty-four months from the effective date of the Resale Registration Statement (as defined below). The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the '1933 Act') and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the 'Resale Registration Statement'). This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Silexion Therapeutics Silexion Therapeutics Corp is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. These forward-looking statements are generally identified by terminology such as 'may', 'should', 'could', 'might', 'plan', 'possible', 'project', 'strive', 'budget', 'forecast', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. For example, the Company is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) whether Silexion is able to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) whether Silexion succeeds at maintaining the listing of its securities on the Nasdaq Capital Market. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company Contact: Silexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFO [email protected]
